Serum angiostatin levels in patients with Behçet’s disease: does angiogenesis play a role in the pathogenesis of Behçet’s disease?

References

• Cekmen M, Evereklioglu C, Er H, Inalöz HS, Doganay S, Türköz Y, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome. Int J Dermatol. 2003;42(11):870–5.
   Web of Science ®Google Scholar
• Direskenli H. Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60(11):996–1002.
   Web of Science ®Google Scholar
• Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanism, disease association and management. Curr Pharm Des. 2012;18(11):1478–93.
   Web of Science ®Google Scholar
• Kamoun M, Houman MH, Hamzaoui A, Hamzaoui K. Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet’s disease. Tissue Antigens. 2008;72(6):581–5.
   Web of Science ®Google Scholar
• Chavakis T, Athanasopoulos A, Rhee JS, Orlova V, Schmidt-Wöll T, Bierhaus A, et al. Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood. 2005;105(3):1036–43.
   PubMed Web of Science ®Google Scholar
• Weber AJ, de Bandt M. Angiogenesis: general mechanisms and implications for rheumatoid arthritis. Joint Bone Spine. 2000;67(5):366–83.
   Web of Science ®Google Scholar
• Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med. 2002;6(3):357–76.
   Web of Science ®Google Scholar
• Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet’s disease: high levels may indicate vascular involvement. Int J Dermatol. 2009;48(3):259–64.
   Web of Science ®Google Scholar
• Sari RA, Kiziltunç A, Taysi S, Akdemir S, Gündoğdu M. Levels of soluble E-selectin in patients with active Behcet’s disease. Clin Rheumatol. 2005;24(1):55–9.
   Web of Science ®Google Scholar
• Hamzaoui K, Maître B, Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet’s disease. Clin Exp Rheumatol. 2009;27(2):52–7.
   Google Scholar
• Bozoglu E, Dinc A, Erdem H, Pay S, Simsek I, Kocar IH. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet’s patients with venous thrombosis. Clin Exp Rheumatol. 2005;23(4):42–8.
   Google Scholar
• Yalçin B, Arda N, Tezel GG, Erman M, Alli N. Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behçet’s disease. Anal Quant Cytol Histol. 2006;28(6):303–9.
   Web of Science ®Google Scholar
• Wahl ML, Moser T, Pizzo SV. Angiostatin and anti-angiogenic therapy in human disease. Recent Prog Horm Res. 2004;59:73–104.
   PubMedGoogle Scholar
• Wahl ML, Grant DS. Effects of microenviromental extracellular pH and extracellular matrix proteins on angiostatin’s activity and on intracellular pH. Gen Pharmacol. 2000;35(5):1–10.
   Google Scholar
• Szekanecz Z, Besenyei T, Paragh G, Koch AE. New insights in synovial angiogenesis. Joint Bone Spine. 2010;77(1):13–9.
   Web of Science ®Google Scholar
• Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 2001;152(6):1247–54.
   Web of Science ®Google Scholar
• Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J. 2002;16(2):267–9.
   PubMedGoogle Scholar
• Gok M, Erdem H, Gogus F, Yilmaz S, Karadag O, Simsek I, et al. Relationship of ultrasonographic findings with synovial angiogenesis modulators in different forms of knee arthritides. Rheumatol Int. 2013;33(4):879–85.
   Web of Science ®Google Scholar
• International Study Group for Behçet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335(8697):1078–80.
   PubMed Web of Science ®Google Scholar
• Bhakta BB, Brennan P, James T, Chamberlein MA, Noble BA, Silman AJ. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38(8):728–33.
   Web of Science ®Google Scholar
• Onder M, Gurer MA. Behçet’s disease: an enigmatic vasculitis. Clin Dermatol. 1999;17(5):571–6.
   Web of Science ®Google Scholar
• Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet’s disease: a pilot study. Clin Rheumatol. 2005;24(4):324–9.
   Web of Science ®Google Scholar
• Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, et al. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet’s disease. Arthritis Rheum. 2003;48(7):2025–35.
   Web of Science ®Google Scholar
• Kayikçioğlu M, Aksu K, Hasdemir C, Keser G, Turgan N, Kültürsay H, et al. Endothelial functions in Behçet’s disease. Rheumatol Int. 2006;26(4):304–8.
   Web of Science ®Google Scholar
• Aydıntug AO, Tokgöz G, D’Cruz DP, Gürler A, Cervera R, Düzgün N, et al. Antibodies to endothelial cells in patients with Behçet’s disease. Clin Immunol Immunopathol. 1993;67(2):157–62.
   Google Scholar
• Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet’s disease. J Am Coll Cardiol. 2001;37(2):517–20.
   PubMed Web of Science ®Google Scholar
• Oflaz H, Mercanoglu F, Karaman O, Kamali S, Erer B, Genchellac H, et al. Impaired endothelium-dependent flow-mediated dilation in Behçet’s disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract. 2005;59(7):777–82.
   Web of Science ®Google Scholar
• Douglas JV, Ursula F. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract Res Clin Rheumatol. 2006;20(5):941–7.
   Web of Science ®Google Scholar
• Pandya NM, Dhalla SN, Santani DD. Angiogenesis — a new target for future therapy. Vascul Pharmacol. 2006;44(5):265–74.
   Web of Science ®Google Scholar
• Habibagahi Z, Habibagahi M, Heidari M. Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet’s disease. Mod Rheumatol. 2010;20(2):154–9.
   Web of Science ®Google Scholar
• Nam EJ, Han SW, Kim SU, Cho JH, Sa KH, Lee WK, et al. Association of vascular endothelial growth factor gene polymorphisms with Behçet disease in a Korean population. Hum Immunol. 2005;66(10):1068–75.
   Web of Science ®Google Scholar
• Salvarani C, Boiardi L, Casali B, Olivieri I, Ciancio G, Cantini F, et al. Endothelial nitric oxide synthase gene polymorphisms in Behçet’s disease. J Rheumatol. 2002;29(3):535–40.
   Web of Science ®Google Scholar
• Salvarani C, Boiardi L, Casali B, Olivieri I, Cantini F, Salvi F, et al. Vascular endothelial growth factor gene polymorphisms in Behçet’s disease. J Rheumatol. 2004;31(9):1785–9.
   Web of Science ®Google Scholar
• Hamzaoui K, Ayed K, Hamza M, Hamzaoui A. VEGF and mRNA VEGF expression in CSF from Behçet’s disease with neurological involvement. J Neuroimmunol. 2009;213(1–2):148–53.
   Web of Science ®Google Scholar
• Ozdamar Y, Berker N, Bahar G, Soykan E, Bicer T, Ozkan SS, et al. Inflammatory mediators and posterior segment involvement in ocular Behçet’s disease. Eur J Ophthalmol. 2009;19(6):998–1003.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol. 2005;23(4):455–61.
   Web of Science ®Google Scholar
• Sumariwalla PF, Cao Y, Wu HL, Feldmann M, Paleolog EM. The angiogenesis inhibitor protease-activated kringles 1–5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther. 2003;5(1):32–9.
   Web of Science ®Google Scholar